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Growth differentiation factor 9:bone
morphogenetic protein 15 (GDF9:BMP15)
synergism and protein heterodimerization
Although the title of the paper by Peng et al.
(1) gave the impression that the authors were
working with a puriﬁed growth differentia-
tion factor 9:bone morphogenetic protein 15
(GDF9:BMP15) heterodimer preparation, at
best, what was being tested was a mixture
of BMP15 homodimers (75%) and GDF9:
BMP15 heterodimers (25%), a point made
by the authors early on in the results section.
However, this important point was not re-
iterated, and the hG9:B15 preparation was
misleadingly referred to as a GDF9/BMP15
heterodimer. In this context, there is a lack
of data on characterization of the hG9:B15
preparation; e.g., no silver-stained SDS/
PAGE gels are presented to indicate purity,
and no chemical crosslinking data are pre-
sented in support of heterodimer formation.
Given that GDF9 and BMP15 dimers in-
teract noncovalently, they may be capable
of forming monomers; hence, an equilib-
rium may exist between monomers, het-
erodimers, and homodimers (Fig. 1). The
authors should not have assumed that heter-
odimerization of GDF9 and BMP15 would
take place simply because they were coex-
pressed in the same cells, and copuriﬁcation
of GDF9 along with BMP15 via afﬁnity
chromatography was not sufﬁcient evidence
to establish heterodimer formation. For ex-
ample, a dimer of homodimers (as shown in
Fig.1, part 4) would similarly copurify and
may well be biologically extremely potent.
Peng et al. (1) referred to previous studies
on the cooperative effects ofGDF9andBMP15
and made the assumption that such studies
monitor the actions of two homodimers. This
is not a valid assumption, for the reasons pic-
tured in Fig. 1. Furthermore, in four previous
studies (ref. 2 and references therein), the
coaddition of GDF9 and BMP15 resulted in
a synergistic response, in contrast to the re-
sults of Peng et al., a crucial difference being
that the previous studies did not use GDF9
or BMP15 with modiﬁed mature regions.
A secondary theme of the study by
Peng et al. (1) was species differences in
the bioactivity of GDF9 and BMP15. In par-
ticular, the following question was raised:
“why do mice GDF9 homodimers have
signiﬁcant activity compared with human
homodimers?” Some suggestions were pre-
sented to help explain these species differ-
ences, but the presence of an Arg residue in
mouse GDF9 at position 391 (as opposed
to a Gly residue for human GDF9) is likely
to be the crucial factor when explaining
these bioactivity differences (3).
The cell surface receptors used by GDF9
and BMP15 were the central issue of the
model presented by Peng et al. (ﬁgure 7 in
ref. 1). Although the authors referred in the
text to the type 1 receptor of GDF9 as activin
receptor-like kinase (ALK) 4/5/7, the ﬁgure
depicted that this receptor was ALK4; how-
ever, no experimental evidence was pre-
sented to support this. Additionally,
published results show that overexpression
of ALK4 in human granulosa cells does not
affect the GDF9 response, whereas ALK5
overexpression results in a very signiﬁcant
increase in the GDF9 response (4). We do
ﬁnd the suggestion of Peng et al. for the
involvement of a BMPR2:ALK4/5/7:ALK6
complex as the signaling mediator of the
putative GDF9:BMP15 heterodimer to be
very reasonable. In fact, this suggestion
has been made previously (5).
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Fig. 1. Potential structural forms of BMP15 (solid) and
GDF9 (clear) mature regions: monomers (1), heterodimers
(2), homodimers (3), and a dimer of homodimers (4).
These different forms may well be in a dynamic equilib-
rium, given that BMP15 and GDF9 mature regions do not
form covalent dimers. A further extension of 4 would be
higher-order noncovalent multimers or aggregates. All of
these forms would result in the same banding pattern in
silver-stained SDS/PAGE gels or Western blots.
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